Curated News
By: NewsRamp Editorial Staff
August 13, 2024
Clene Inc. Makes Strides in Developing CNM-Au8 to Address Neurodegenerative Conditions
Discuss on Reddit
Discuss on SubstackTLDR
- Investors can gain insights into Clene's promising drug candidate CNM-Au8 for neurodegenerative diseases, potentially providing a competitive advantage.
- CNM-Au8 enhances cellular energy production and utilization, crucial for maintaining neuronal health in neurodegenerative diseases.
- Clene's drug candidate CNM-Au8 has the potential to improve mitochondrial health and protect neuronal function, offering hope for better treatment of neurodegenerative diseases.
- Clene's recent presentation at the Emerging Growth Conference 73 highlighted new findings and information about their lead drug candidate, CNM-Au8.
Impact - Why it Matters
This news matters because it highlights the progress of a clinical-stage biopharmaceutical company in developing a drug candidate to treat neurodegenerative diseases, offering hope to patients and potential investment opportunities.
Summary
Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). In the recent Emerging Growth Conference 73 on July 17-18, 2024, CEO Rob Etherington and CFO Morgan Brown presented new findings and information about the company and its lead drug candidate, pertinent to current and potential investors.
Clene has conducted five Phase 2 clinical trials, three with long-term extensions, and three expanded access programs (with additional studies ongoing) to evaluate the safety and efficacy of CNM-Au8. The global ALS treatment market is poised for growth, driven by an aging population and limited current treatment options. CNM-Au8 works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health, and is at a deficit in neurodegenerative diseases.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene Inc. Makes Strides in Developing CNM-Au8 to Address Neurodegenerative Conditions
